At a glance
ClinicalIndex Comparison Record- ✓Newly diagnosed non-disseminated intrinsic diffuse brainstem glioma
- ✓KPS ≥50 (age >16) or Lansky Performance Score ≥50 (age ≤16) within two weeks prior to registration
- ✓No prior chemotherapy
- ✓No prior radiation therapy
- ✕Disseminated intrinsic diffuse brainstem glioma
- ✕Currently taking enzyme-inducing anticonvulsant drugs
- ✕Known allergy to topical or systemic imidazoles (clotrimazole, ketoconazole, miconazole, econazole)
- ✕Receiving any other anticancer or experimental drug therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Trial of R115777 and XRT in Pediatric Patients With Newly Diagnosed Non-Disseminated Intrinsic Diffuse Brainstem Gliomas
In Brief
A Phase 2 clinical trial evaluating radiation therapy and tipifarnib for Untreated Childhood Brain Stem Glioma. Completed, enrolled 51 participants across 1 site.
Detailed Summary
Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Tipifarnib may make tumor cells more sensitive to radiation therapy. Combining tipifarnib with radiation therapy may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of tipifarnib to see how well it works when given together with radiation therapy in treating young patients with newly diagnosed brain stem glioma. (Phase I closed to accrual as of 1/19/06)
Study Details
Timeline
Interventions
Undergo radiotherapy
Given orally